Managing empowerment and control in an intranet environment

An intranet increases in sophistication and complexity as it evolves. This evolution leads to an increasing need for control over the intranet. However, this is a contentious issue, as an intranet is deemed to be an empowering technology. Consequently, intranet control systems must balance empowerment and control so as not to negate each other. This paper investigates intranet control activities and their effect on users' perceptions of empowerment throughout the evolution of an intranet in Hewlett Packard (Ireland). The growth of the intranet is charted as a six-stage model that illustrates an evolution of purpose, control and empowerment. The control strategies for managing the intranet implemented at each stage are investigated, and their resultant effects on empowerment are evaluated. The study reveals the importance of balancing control strategies with empowerment initiatives in managing intranet environments. Based on the evidence available, the study recommends the implementation of specific controls at particular stages in the evolution of an intranet in order to achieve control systems that balance empowerment and control

E-Business Innovation and Process Management

presents a multiple case study investigation of email system monitoring and control. The study examines the interaction between key elements of email control identified by previous researchers, and considers the role of such controls at various implementation phases. The findings reveal eight major elements to be particularly important in monitoring and controlling email systems within the organizations studied. These are: (1) form a cross-functional email system management team; (2) implement and regularly update email management software; (3) formulate a detailed and legally sound email policy; (4) engage in structured email system training; (5) create and maintain ongoing awareness of email policy; (6) engage in a process of hybrid feedback and control based email monitoring; (7) firmly enforce discipline in accordance with the email policy; and (8) conduct regular reviews and updates of the email management program

Usability of Mobile Devices and intelligently adapting to a User's needs

Usability is defined in ISO 9241 (1998) as the extent to which a product can be used by specified users to achieve specified goals with effectiveness, efficiency and satisfaction. Usability in relation to mobile services i.e. services that run on Mobile Phones and PDAs must look at the mobile user and surmise what interfaces for mobile services are appreciated and anticipated by the user. This paper will cover the area of usability issues when developing Mobile services. It will look at the mobile users and will propose a system that will store and utilise users' context information to help a user carry out a task. It will formulate a structure that allows applications to learn the significance and interrelations of people, places, objects and documents. By knowing the significance and relationships between objects and data, applications can always provide the user with the most relevant data and build up a context for user interaction

Personalized fully multimodal journey planner

We present an advanced journey planner designed to help travellers to take full advantage of the increasingly rich, and consequently more complex offering of mobility services available in modern cities. In contrast to existing systems, our journey planner is capable of planning with the full spectrum of mobility services; combining individual and collective, fixed-schedule as well as on-demand modes of transport, while taking into account individual user preferences and the availability of transport services. Furthermore, the planner is able to personalize journey planning for each individual user by employing a recommendation engine that builds a contextual model of the user from the observation of user’s past travel choices. The planner has been deployed in four large European cities and positively evaluated by hundreds of users in field trialsPeer ReviewedPostprint (published version

Contract Modelling for Digital Business Ecosystems

The aim of this paper is to discuss the legal and technical issues of creating legally binding contracts in a digital ecosystem and to present the solution created for the DBE (Digital Business Ecosystem) project[1]. We investigate the legal implications of electronic contracts and digital signatures, and also take a brief look at the types of clauses that make up a contract. The DBE contract model for creating contracts and contract templates is presented, along with the tools created for editing these contracts as part of the DBE project

A new free-surface stabilization algorithm for geodynamical modelling:Theory and numerical tests

The surface of the solid Earth is effectively stress free in its subaerial portions, and hydrostatic beneath the oceans. Unfortunately, this type of boundary condition is difficult to treat computationally, and for computational convenience, numerical models have often used simpler approximations that do not involve a normal stress-loaded, shear-stress free top surface that is free to move. Viscous flow models with a computational free surface typically confront stability problems when the time step is bigger than the viscous relaxation time. The small time step required for stability (<2. Kyr) makes this type of model computationally intensive, so there remains a need to develop strategies that mitigate the stability problem by making larger (at least ~10 Kyr) time steps stable and accurate. Here we present a new free-surface stabilization algorithm for finite element codes which solves the stability problem by adding to the Stokes formulation an intrinsic penalization term equivalent to a portion of the future load at the surface nodes. Our algorithm is straightforward to implement and can be used with both Eulerian or Lagrangian grids. It includes α and β parameters to respectively control both the vertical and the horizontal slope-dependent penalization terms, and uses Uzawa-like iterations to solve the resulting system at a cost comparable to a non-stress free surface formulation. Four tests were carried out in order to study the accuracy and the stability of the algorithm: (1) a decaying first-order sinusoidal topography test, (2) a decaying high-order sinusoidal topography test, (3) a Rayleigh-Taylor instability test, and (4) a steep-slope test. For these tests, we investigate which α and β parameters give the best results in terms of both accuracy and stability. We also compare the accuracy and the stability of our algorithm with a similar implicit approach recently developed by Kaus et al. (2010). We find that our algorithm is slightly more accurate and stable for steep slopes, and also conclude that, for longer time steps, the optimal α controlling factor for both approaches is ~2/3, instead of the 1/2 Crank-Nicolson parameter inferred from a linearized accuracy analysis. This more-implicit value coincides with the velocity factor for a Galerkin time discretization applied to our penalization term using linear shape functions in time

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

Background Non-alcoholic steatohepatitis (NASH) is a common type of chronic liver disease that can lead to cirrhosis. Obeticholic acid, a farnesoid X receptor agonist, has been shown to improve the histological features of NASH. Here we report results from a planned interim analysis of an ongoing, phase 3 study of obeticholic acid for NASH. Methods In this multicentre, randomised, double-blind, placebo-controlled study, adult patients with definite NASH,non-alcoholic fatty liver disease (NAFLD) activity score of at least 4, and fibrosis stages F2–F3, or F1 with at least oneaccompanying comorbidity, were randomly assigned using an interactive web response system in a 1:1:1 ratio to receive oral placebo, obeticholic acid 10 mg, or obeticholic acid 25 mg daily. Patients were excluded if cirrhosis, other chronic liver disease, elevated alcohol consumption, or confounding conditions were present. The primary endpointsfor the month-18 interim analysis were fibrosis improvement (≥1 stage) with no worsening of NASH, or NASH resolution with no worsening of fibrosis, with the study considered successful if either primary endpoint was met. Primary analyses were done by intention to treat, in patients with fibrosis stage F2–F3 who received at least one dose of treatment and reached, or would have reached, the month 18 visit by the prespecified interim analysis cutoff date. The study also evaluated other histological and biochemical markers of NASH and fibrosis, and safety. This study is ongoing, and registered with ClinicalTrials.gov, NCT02548351, and EudraCT, 20150-025601-6. Findings Between Dec 9, 2015, and Oct 26, 2018, 1968 patients with stage F1–F3 fibrosis were enrolled and received at least one dose of study treatment; 931 patients with stage F2–F3 fibrosis were included in the primary analysis (311 in the placebo group, 312 in the obeticholic acid 10 mg group, and 308 in the obeticholic acid 25 mg group). The fibrosis improvement endpoint was achieved by 37 (12%) patients in the placebo group, 55 (18%) in the obeticholic acid 10 mg group (p=0·045), and 71 (23%) in the obeticholic acid 25 mg group (p=0·0002). The NASH resolution endpoint was not met (25 [8%] patients in the placebo group, 35 [11%] in the obeticholic acid 10 mg group [p=0·18], and 36 [12%] in the obeticholic acid 25 mg group [p=0·13]). In the safety population (1968 patients with fibrosis stages F1–F3), the most common adverse event was pruritus (123 [19%] in the placebo group, 183 [28%] in the obeticholic acid 10 mg group, and 336 [51%] in the obeticholic acid 25 mg group); incidence was generally mild to moderate in severity. The overall safety profile was similar to that in previous studies, and incidence of serious adverse events was similar across treatment groups (75 [11%] patients in the placebo group, 72 [11%] in the obeticholic acid 10 mg group, and 93 [14%] in the obeticholic acid 25 mg group). Interpretation Obeticholic acid 25 mg significantly improved fibrosis and key components of NASH disease activity among patients with NASH. The results from this planned interim analysis show clinically significant histological improvement that is reasonably likely to predict clinical benefit. This study is ongoing to assess clinical outcomes

Design and Development of a Flexible, Battery-free, Wireless, Wearable Electronic Nose for Disease Detection

The objective of this project was to develop a wearable device that would be able to diagnose COVID-19 in a quick and cost-effective manner. To solve this problem, we combined previously developed technology of an electronic nose (e-nose) made up of an array of carbon nanotube (CNT)/polymer composites and wireless, battery free, flexible technology. This device is able to passively interact with volatile organic compounds (VOCs) in the air, harvest power from a mobile device, gather data from each sensor, and store that data on a secure database that can be analyzed and tested against previously gathered data or trained algorithms. The device was fully developed and manufactured on a flexible printed circuit board (PCB). The finished device was verified in the lab against VOCs that are commonly expelled from the body. An android application was developed to read data from the sensors and write the data to a secure database for later analysis. A human study was then set up to test the device against patients with COVID-19. The study was set up to compare the responses of patients that tested positive for COVID-19 and those who tested negative but showed similar symptoms. Advisor: Eric Markvick